Abstract | OBJECTIVE: METHODS: A method to measure hypocretin-1 in 100 microL of crude CSF sample was established and validated. CSF hypocretin-1 was measured in 42 narcolepsy patients (ages 16-70 years), 48 healthy controls (ages 22-77 years,) and 235 patients with various other neurologic conditions (ages 0-85 years). RESULTS: CONCLUSIONS: Undetectable CSF hypocretin-1 levels are highly specific to narcolepsy and rare cases of GBS. Measuring hypocretin-1 levels in the CSF of patients suspected of narcolepsy is a useful diagnostic procedure. Low hypocretin levels are also observed in a large range of neurologic conditions, most strikingly in subjects with head trauma. These alterations may reflect focal lesions in the hypothalamus, destruction of the blood brain barrier, or transient or chronic hypofunction of the hypothalamus. Future research in this area is needed to establish functional significance.
|
Authors | B Ripley, S Overeem, N Fujiki, S Nevsimalova, M Uchino, J Yesavage, D Di Monte, K Dohi, A Melberg, G J Lammers, Y Nishida, F W Roelandse, M Hungs, E Mignot, S Nishino |
Journal | Neurology
(Neurology)
Vol. 57
Issue 12
Pg. 2253-8
(Dec 26 2001)
ISSN: 0028-3878 [Print] United States |
PMID | 11756606
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.)
|
Chemical References |
- Carrier Proteins
- HCRT protein, human
- Intracellular Signaling Peptides and Proteins
- Neuropeptides
- Orexins
|
Topics |
- Carrier Proteins
(cerebrospinal fluid)
- Humans
- Intracellular Signaling Peptides and Proteins
- Narcolepsy
(cerebrospinal fluid)
- Nervous System Diseases
(cerebrospinal fluid)
- Neuropeptides
(cerebrospinal fluid)
- Orexins
- Radioimmunoassay
- Sensitivity and Specificity
|